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Abstract
Background Clinical research on arrhythmogenic car-
diomyopathy (ACM) is typically limited by small pa-
tient numbers, retrospective study designs, and in-
consistent definitions.
Aim To create a large national ACM patient cohort
with a vast amount of uniformly collected high-quality
data that is readily available for future research.
Methods This is a multicentre, longitudinal, obser-
vational cohort study that includes (1) patients with
a definite ACM diagnosis, (2) at-risk relatives of ACM
patients, and (3) ACM-associated mutation carriers.
At baseline and every follow-up visit, a medical history
as well information regarding (non-)invasive tests is
collected (e.g. electrocardiograms, Holter recordings,
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imaging and electrophysiological studies, pathology
reports, etc.). Outcome data include (non-)sustained
ventricular and atrial arrhythmias, heart failure, and
(cardiac) death. Data are collected on a research elec-
tronic data capture (REDCap) platform in which every
participating centre has its own restricted data access
group, thus empowering local studies while facilitat-
ing data sharing.
Discussion The Netherlands ACM Registry is a na-
tional observational cohort study of ACM patients and
relatives. Prospective and retrospective data are ob-
tained at multiple time points, enabling both cross-
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sectional and longitudinal research in a hypothesis-
generating approach that extends beyond one spe-
cific research question. In so doing, this registry aims
to (1) increase the scientific knowledge base on dis-
ease mechanisms, genetics, and novel diagnostic and
treatment strategies of ACM; and (2) provide educa-
tion for physicians and patients concerning ACM, e.g.
through our website (www.acmregistry.nl) and patient
conferences.
Keywords Cardiomyopathies · Arrhythmogenic right
ventricular dysplasia · Research design · Registries
Introduction
Arrhythmogenic cardiomyopathy (ACM), including its
major subform arrhythmogenic right ventricular car-
diomyopathy, is a relatively rare heart muscle disease
that affects approximately 1:1,000–5,000 people [1, 2].
It is characterised by an increased risk of ventricular
arrhythmias, sudden cardiac death, and progressively
deteriorating ventricular function due to intercalated
disk remodelling and fibro-fatty myocardial replace-
ment [3]. ACM can present both in isolated and in
familial forms and is consistent with an autosomal
dominant inheritance pattern with incomplete pene-
trance and variable expressivity.
ACM was first described by Marcus et al. in 1982
[4]. Since then, considerable advancements have been
made that have improved our knowledge of this clini-
cal entity. Nonetheless, management of ACM is com-
plex due to the clinical heterogeneity of the disease,
and optimal treatment protocols including risk strati-
fication are still under development [5–8]. Studies on
ACM often suffer from limitations secondary to the
low prevalence and slow progression of the disease,
i. e. many studies have insufficient statistical power
and are restricted to retrospective follow-up since de-
velopment of disease and (arrhythmic) endpoints is
slow [9]. Additionally, the lack of uniform definitions
complicates comparison of results among studies [10].
In order to overcome these limitations, we designed
a national registry to include all Dutch ACM patients,
first-degree relatives and/or carriers of ACM-associ-
ated pathogenic mutations. Observational clinical
data are systematically collected (both retrospectively
and prospectively) from first visit to last follow-up
using uniform data collection instruments. In so do-
ing, we aim to create a large national ACM patient
cohort with a vast amount of uniformly collected
high-quality data that is readily available for future
research. The goals of this registry are to (1) increase
the scientific knowledge base on disease mechanisms,
genetics, and novel diagnostic and treatment strate-
gies of ACM; and (2) use this platform to provide




The Netherlands ACM Registry is a national, multi-
centre observational cohort that is coordinated by
the Netherlands Heart Institute (NHI, Utrecht, The
Netherlands). The registry follows the Code of Con-
duct and the Use of Data in Heath Research and
the national inclusion of patients is exempt from
the Medical Research Involving Human Subjects Act
(WMO) as per judgement of the Medical Ethics Com-
mittee (METC 18-126/C, Utrecht, The Netherlands).
The ACM Registry is registered at the Netherlands
Trial Registry, project 7097 (www.trialregister.nl).
Objectives
The ACM Registry aims to (1) facilitate research on
ACM disease mechanisms, genetics, diagnosis, prog-
nosis, and treatment strategies; and (2) provide educa-
tion for physicians and patients concerning ACM, e.g.
through our website (www.acmregistry.nl) and patient
conferences.
Study population
Eligible for inclusion in the ACM Registry are: (1) in-
dex patients with a definite ACM diagnosis according
to the diagnostic Task Force Criteria (TFC) [11] and
in whom alternative diagnoses are excluded; (2) all
first-degree relatives of ACM patients regardless of the
index patient’s genetic testing results, which also in-
cludes relatives who are asymptomatic, who refuse ge-
netic or cardiac testing, or those who are known to be
mutation-negative (i. e. serve as control subjects); and
(3) all carriers of pathogenic mutations in genes asso-
ciated with ACM, regardless of their phenotype. After
inclusion, a unique study ID is assigned to each reg-
istry enrolee by the NHI study coordinator to ensure
the enrolee’s privacy. The study ID can be traced back
to the enrolee only by the NHI coordinator and the
local coordinator from the medical centre at which
the enrolee is recruited. Currently, patients are re-
cruited through all eight academic medical centres in
the Netherlands.
Data collection
Patient data are collected by researchers in the study
centres using standardised data collection instru-
ments hosted in REDCap (Research Electronic Data
Capture, Vanderbilt University, Nashville, TN, USA)
[12]. Supplementary Tab. 1 shows an overview of
the collected clinical data with their definitions. In
short, a comprehensive medical history is obtained,
including demographics, symptoms, medication use,
family history, molecular genetic analysis, pregnancy,
and exercise history. Test results are ascertained
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at first presentation and at every follow-up visit,
including laboratory values, (signal averaged) elec-
trocardiograms, Holter recordings, exercise testing,
electrophysiological studies, cardiac imaging, ventric-
ular/coronary cine-angiograms, and cardiac tissue
from biopsy or surgery. When available, raw data
such as electrocardiogram tracings and de-identi-
fied images from cardiac imaging are stored through
the Extensible Neuroimaging Archive Toolkit (XNAT,
Washington University School of Medicine, St. Louis,
MO, USA) software application for validation pur-
poses and retrospective collection of newly identified
relevant parameters. In addition, all interventions
such as implantable cardioverter-defibrillator (ICD)
placement and endocardial/epicardial ablations are
recorded. As the registry design is observational,
management and follow-up intervals remain at the
discretion of the participant’s own cardiologist. Out-
come data that are collected include (non-)sustained
ventricular arrhythmias, ICD interventions, atrial ar-
rhythmias, heart failure symptoms, hospitalisations,
and (cardiac) death. The complete data dictionary
and data collection instruments are available for
download upon request.
Data quality assurance
Data are acquired from routine clinical care in mul-
tiple academic centres that are all members of the
Dutch Heritable Cardiomyopathy working group.
Within this working group, clinical protocols regard-
ing the diagnosis, genetic analysis and clinical care
of cardiomyopathy patients are harmonised, which
enhances the uniformity and quality of the data in
this observational cohort. Uniform data collection is
ensured by standardised data collection instruments
built in REDCap accompanied by a detailed standard
operating procedure document. Data entry fields
are provided with entry instructions and are pre-
programmed to accept values only within a possible
range. The status of every data collection instrument
is recorded: the default setting of ‘incomplete’ may
be upgraded to ‘unverified’ when data are entered
but not yet verified, and to ‘complete’ when data
verification has been performed by an experienced
researcher (rights are pre-specified in the researcher’s
user account). All data access, entries and changes are
recorded in a detailed audit trail by REDCap. The di-
agnostic criteria for ACM [11], dilated cardiomyopathy
[13] and non-compaction cardiomyopathy [14, 15] are
calculated by pre-programmed algorithms. Fulfilment
of these criteria is thereby automatically determined
in real time while entering the data to ensure accurate
phenotyping.
Data sharing and logistics
The REDCap database is hosted by the NHI. Security,
data protection, and IT support are provided by the
NHI Durrer Centre. Access to the ACM database is
restricted to specific data access groups correspond-
ing to the participating centres (Fig. 1) to ensure that
researchers can access data only from patients known
in their own centre. Only NHI research coordina-
tors have access to the full database for quality assur-
ance, database support, prevention of duplicate en-
tries, and coordination of family linkage. Local co-
ordinators are appointed in every centre to super-
vise data access and entry by local researchers. To-
gether with the NHI coordinators, these local coordi-
nators form the ACM Registry working group, which
is tasked with discussing and coordinating data re-
quests for multicentre studies. Prior to data release,
the study protocol with research question, inclusion
criteria, required data, and list of potential co-authors
is approved by all collaborators to ensure scientific in-
tegrity. Researchers are free to use patient data within
their data access group for local studies, provided that
the ACM Registry and REDCap database are acknowl-
edged.
Results
As of 1 February 2018, the ACM Registry contains 850
individual patient records. Among these, 228 (27%)
are ACM index patients and 622 (73%) are at-risk rel-
atives, among whom 114 (18%) fulfil a definite ACM
diagnosis. Pathogenic mutations are found in 69%
of index patients (most commonly in plakophilin-2;
52%). An overview of the clinical characteristics is
provided in Tab. 1.
Follow-up information is currently available for 384
(45%) patients, among whom 210 (92%) are index pa-
tients and 174 (28%) relatives. Median follow-up is
9.5 years (interquartile range 4.6–16.2). The available
clinical tests are outlined in Tab. 1. At least one elec-
trocardiogram is available for almost all index patients
(n= 215, 94%) and most relatives (n= 459, 74%), while
Holter monitoring is available in the majority of both
groups (n= 166, 73% and n= 329, 53%, respectively).
An electrophysiological study is available in 133 (58%)
index patients and 36 (6%) family members. Almost all
index patients (n= 210, 92%) and most family mem-
bers (n= 366, 59%) underwent at least one modal-
ity of cardiac imaging, with echocardiography being
the most common (n= 206, 90% and n= 344, 55%, re-
spectively), followed by cardiac magnetic resonance
(n= 170, 75% and n= 219, 35%, respectively), and an-
giography (n=150, 66% and n= 43, 7%, respectively).
Discussion
Clinical research on ACM is often limited by (1) small
patient numbers; (2) retrospective study designs; and
(3) inconsistent data definitions, leading to inability
to compare results across studies [10]. To overcome
these limitations, collaboration and sharing of exper-
tise is paramount.
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Fig. 1 Graphic represen-
tation of the Netherlands
ACM Registry: data ac-
cess, logistics and shar-
ing. The ACM Registry is
hosted on a central server
at the Netherlands Heart
Institute. The database is
divided in 8 data-access
groups, managed by local
coordinators of each partic-
ipating centre. The central
coordinators have access
to the complete database
for quality control and co-
ordination of collaboration.
The central coordinators to-
gether with the local co-
ordinators form the ACM
Registry working group
In the past, collaborative ACM research using
multinational transatlantic databases has provided
strong evidence on several clinically relevant prob-
lems including diagnosis, genotype-phenotype corre-
lations and family screening [11, 16–18]. While Dutch
ACM patients have previously been enrolled in these
studies, data collection was largely cross-sectional
and hypothesis-driven, hence only applicable to one
specific study. This, as well as the introduction of
new data collection guidelines (e.g. standardised
case record forms and audit trails), demanded a new
platform. With the Netherlands ACM Registry, we
designed a platform to create and maintain a large
observational longitudinal patient cohort that contin-
ues and expands our prior database to a user-friendly
and sustainable ACM Registry.
In the Netherlands ACM Registry, we use standard-
ised protocols to ensure uniform, high-quality data.
All these data are readily available to facilitate collab-
orative ACM research. A wide range of demographic
and clinical data are collected including disease phe-
notype, genotype, treatment, and outcomes at mul-
tiple time points, enabling both cross-sectional and
longitudinal studies in a hypothesis-generating ap-
proach. Data validation occurs through several auto-
mated validation processes (e.g. real-time calculation
of diagnostic TFC) which undergo an additional man-
ual check by experts (e.g. electrocardiogram over-read
by trained electrophysiologists). Final ACM diagnosis
is manually confirmed by experts. The phenotype al-
gorithms aid long-term sustainability of the database,
as they can easily be altered if the diagnostic guide-
lines are modified. In addition, data validity and sus-
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Table 1 Clinical characteristics and available tests of 850 patients included in the Netherlands ACMRegistry as of 1 February
2018
Patient characteristics All Index patients Family members
Number 850 (100.0%) 228 (26.8%) 622 (73.2%)
Age at presentation (years) 38 [24–50] 39 [27–46] 38 [21–52]
Male sex 443 (52.1%) 161 (70.6%) 282 (45.3%)
ACM diagnosisa
– definite 342 (40.2%) 228 (100%) 114 (18.3%)
– borderline 90 (10.6%) n. a. 90 (14.5%)
Genetic testing performed 702 (82.6%) 226 (99.1%) 476 (76.5%)
Pathogenic mutation 458 (65.2%) 157 (69.5%) 301 (63.2%)
– PKP2 361 (51.4%) 118 (52.2%) 243 (51.1%)
– DSP 7 (1.0%) 4 (1.8%) 3 (0.6%)
– JUP 0 (0.0%) 0 (0.0%) 0 (0.0%)
– DSG2 14 (2.0%) 6 (2.7%) 8 (1.7%)
– DSC2 11 (1.6%) 5 (2.2%) 6 (1.3%)
– PLN 63 (9.0%) 24 (10.6%) 39 (8.2%)
– other 12 (1.7%) 5 (2.2%) 7 (1.5%)
– multipleb 9 (1.3%) 4 (1.8%) 5 (1.1%)
Test results available (≥1)
ECG 674 (79.3%) 215 (94.3%) 459 (73.8%)
SAECG 88 (10.4%) 50 (21.9%) 38 (6.1%)
ETT 397 (46.7%) 166 (72.8%) 231 (37.1%)
Holter monitoring 495 (58.2%) 166 (72.8%) 329 (52.9%)
Imaging 576 (67.8%) 210 (92.1%) 366 (58.8%)
– echo 550 (64.7%) 206 (90.4%) 344 (55.3%)
– MRI 389 (45.8%) 170 (74.6%) 219 (35.2%)
– angiogram 193 (22.7%) 150 (65.8%) 43 (6.9%)
EPS 169 (19.9%) 133 (58.3%) 36 (5.8%)
Tissue biopsy 115 (13.5%) 89 (39.0%) 26 (4.2%)
Follow-up
Follow-up available 384 (45.2%) 210 (92.1%) 174 (28%)
– duration (years) 9.5 [4.6–16.2] 12.2 [5.1–20.0] 7.6 [3.3–12.1]
ICD implanted 235 (27.6%) 165 (72.4%) 70 (11.3%)
Sustained VA 196 (23.1%) 163 (71.5%) 33 (5.3%)
Heart transplantation 7 (0.8%) 5 (2.2%) 2 (0.3%)
Death 53 (6.2%) 36 (15.8%) 17 (2.7%)
ACM arrhythmogenic cardiomyopathy, DSC2 desmocollin-2, DSG2 desmoglein-2, DSP desmoplakin, ECG electrocardiogram, EPS electrophysiologic study,
ETT exercise treadmill test, ICD implantable cardioverter-defibrillator, JUP junction plakoglobin, MRI magnetic resonance imaging, PKP2 plakophilin-2,
PLN phospholamban, SAECG signal-averaged electrocardiogram, TFC task force criteria, VA ventricular arrhythmia
aDefinite ACM is defined as modified TFC score ≥4; borderline ACM is defined as modified TFC score 3
bDigenic or compound heterozygous
tainability are assured by storing raw data such as de-
identified cardiac magnetic resonance images, which
can be re-evaluated if new insights are gained.
One limitation of our registry is the observational
nature, in which we do not impose standard clini-
cal evaluation intervals or interfere with diagnostic
and/or treatment strategies. This may introduce cen-
tre-specific differences, which should be accounted
for in every study separately depending on the re-
search question. Furthermore, our registry is pheno-
type-based, meaning that inclusion of patients and
relatives is restricted to families in which at least one
relative has a definite diagnosis of ACM [11] and ACM-
related mutation carriers. Although we consider this
to be a strength to minimise distortion of results by
inclusion of non-ACM patients, this also introduces
limitations: at the present time, our registry cannot
be used to study the differentiation of ACM with dis-
ease-mimicking entities.
Future perspectives
We aim to improve this registry continuously. Fu-
ture perspectives include the expansion of the popu-
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lation to borderline/possible ACM patients. We also
plan to collaborate with existing biobanks for car-
diac tissue, DNA and plasma to facilitate additional
research on disease penetrance and the pathophysi-
ological mechanisms of ACM. The Netherlands ACM
Registry aims to stimulate existing and future (inter-
)national collaboration and transparency in ACM re-
search, not only among researchers but also between
researchers and patients. In the future, we intend to
use this registry as a tool to enable physician and pa-
tient education by means of patient conferences as
well as to provide interested readers with the possibil-
ity to receive updates on current and future research
in newsletters.
Conclusion
The Netherlands ACM Registry is a national observa-
tional cohort of ACM patients and at-risk relatives.
Data collection is performed both prospectively and
retrospectively using a secure online platform that in-
cludes demographic, genetic, and clinical characteris-
tics at multiple time points, enabling both cross-sec-
tional and longitudinal research. By using uniform
variable definitions and automatic data verification,
a user-friendly and sustainable platform is generated.
The final aim of this registry is to (1) increase the
scientific knowledge base of ACM by strong national
collaboration, as well as facilitating potential interna-
tional collaborations; and (2) provide education for
physicians and patients concerning ACM.
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